COMMENTARY: Review: Meglitinide analogues reduce glucose levels in type 2 diabetes, but morbidity and mortality effects are unknown

Ganda, Om P.
November 2007
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p65
Academic Journal
The author reflects upon the results of a clinical study on the effectiveness and safety of meglitinide analogues (MA) in the treatment of type 2 diabetes mellitus. He comments that the MAs improved the glycemic control but the efficacy of MAs and sulfonylureas was not compared in the study. He also mentions the lack of available data in the study, regarding the MA's long-term effects on mortality and morbidity. He also shows a concern towards the long-term safety of thiazolidinediones.


Related Articles

  • Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes. Jin-Sun Chang; Juyoung Shin; Hun-Sung Kim; Kyung-Hee Kim; Jeong-Ah Shin; Kun-Ho Yoon; Bong-Yun Cha; Ho-Young Son; Jae-Hyoung Cho // Diabetes & Metabolism Journal;Feb2013, Vol. 37 Issue 1, p72 

    Background: The aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes. Methods: In this retrospective study, we retrieved data for subjects who were on twice-daily 50 mg vildagliptin for at least 6...

  • Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog. Young, Jason R.; McAdam-Marx, Carrie // Clinical Medicine Insights: Endocrinology & Diabetes;2010, Issue 3, p65 

    Insulin detemir is a long-acting basal insulin approved for use in patients with type 1 (T1DM) or type 2 diabetes (T2DM). Insulin detemir has demonstrated equivalent glycemic control and hypoglycemic risk when compared to insulin glargine, and insulin detemir has generally but not consistently...

  • Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus. Signorovitch, James E.; Wu, Eric Q.; Swallow, Elyse; Kantor, Evan; Fan, Liangyi; Gruenberger, Jean-Bernard // Clinical Drug Investigation;2011, Vol. 31 Issue 9, p665 

    Background and Objective: Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. The aim of this study was to compare 12-week...

  • An Observational Study Goes Where Randomized Clinical Trials Have Not. Frakt, Austin B. // JAMA: Journal of the American Medical Association;3/17/2015, Vol. 313 Issue 11, p1091 

    The article discusses research being done on two classes of drugs used for patients with type 2 diabetes. It references a study by Julia Prentice et al, published in the journal "Value in Health." Topics covered include the association between the use of sulfonylureas and greater mortality, the...

  • Norma TERAPÊUTICA DA DIABETES MELLITUS TIPO 2: METFORMINA Uma Perspectiva Crítica. PINTO, Daniel; HELENO, Bruno; GALLEGO, Rosa; SANTOS, Isabel; SANTIAGO, Luiz Miguel; MARIA, Vasco // Acta Medica Portuguesa;2011, Vol. 24 Issue 2, p331 

    Clinical guidelines have the potential to increase health gains, but also to cause harm. In this opinion article we state some misgivings about the application of the Portuguese National Health Directorate's guideline type 2 diabetes therapy: metformin in primary care. We seek to highlight...

  • Oral hypoglycemic agents in the treatment of type II diabetes. Tal, Alexander // American Family Physician;11/1/1993, Vol. 48 Issue 6, p1089 

    Discusses sulfonylureas and their use as oral hypoglycemic agents in the treatment of non-insulin-dependent (type II) diabetes. Pharmacologic properties; Comparison of oral sulfonylurea drugs; Mechanism of action; Therapeutic results; Side effects; Drug interactions; Biguanides and other drugs.

  • Intensive blood glucose therapy for type 2 diabetics.  // Modern Medicine;Jan99, Vol. 67 Issue 1, p22 

    Discusses the abstract `Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes' by the United Kingdom Prospective Diabetes Study Group published in the September 12, 1998 issue of `Lancet'...

  • Glycaemic control: do no harm. Kelly, L. // South African Family Practice;Feb/Mar2012, Vol. 54 Issue 1, p6 

    The article focuses on gylcemic control for patients with type 2 diabetes (T2DM). It discusses studies on the consequences of tight glycemic control in T2DM patients, including the effect of glycemic control on ambulatory patients and elderly patients with myocardial infarction, stroke and...

  • Assessment of glycaemic control.  // Journal of Endocrinology, Metabolism & Diabetes of South Africa;Mar2012, Vol. 17 Issue 1, pS20 

    The article focuses on the need of the assessment of glycaemic control. It informs that setting targets for both short- and long-term control is essential in treating glycaemia in patients with type 2 diabetes mellitus. It mentions that primary purpose in treating glycaemia is to reduce blood...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics